Kymera Therapeutics advances Phase 2 trials of KT-474 in partnership with Sanofi
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a leader in the biopharmaceutical sector focusing on targeted protein degradation (TPD), has announced a significant expansion of its ongoing ... Read More
Suven Life Sciences announces promising results at 76th American Academy of Neurology Meeting
Suven Life Sciences, a clinical-stage biopharmaceutical company focused on the development of novel treatments for Central Nervous System (CNS) disorders, is set to present significant ... Read More